Figure 1.
Atp6v1c1 knockdown 4T1 cell clone selection and lack of expression of Atp6v1c2 in Atp6v1c1-depleted 4T1 cells.
(a) Atp6v1c1 expression in different 4T1 cells as indicated by western blotting. (b) RT-PCR assays of lung and different 4T1 cells as indicated were performed with gene-specific primers for Atp6v1c1, Atp6v1c2, and β-actin.
Figure 2.
Regular F-actin arrangement was blocked in Atp6v1c1-depleted 4T1 cells.
F-actin Oregon Green® 514 phalloidin staining of different 4T1 cells as indicated. Nuclei were visualized with DAPI. The cells shown are representative of the data (n = 3).
Figure 3.
Atp6v1c1 co-localized with F-actin in 4T1 cells.
Anti-Atp6v1c1 immunostaining and F-actin Oregon Green® 514 phalloidin staining of 4T1 cells. In the merged image, yellow staining showed that F-actin and Atp6v1c1 colocalized in the plasma and plasma membrane of 4T1 cells. The white arrows showed that most of the F-actin and Atp6v1c1 colocalization focused on the plasma membrane. The cells shown are representative of the data (n = 3).
Figure 4.
Verification of shRNA targeting to human ATP6V1C1 in human breast cancer cell lines.
(a) ATP6V1C1 expression in different lentivirus-treated MDA-MB-231 cells as indicated by western blotting. (b) ATP6V1C1 expression in different lentivirus-treated MDA-MB-435s cells as indicated by western blotting.
Figure 5.
Regular F-actin arrangement was blocked in ATP6V1C1-depleted MDA-MB-231 and MDA-MB-435s cells.
F-actin rhodamine phalloidin of different lentivirus-treated cells as indicated. The white arrows showed cells with disrupted actin cytoskeleton compared to control cells. The cells shown are representative of the data (n = 3).